Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding Div RTS (OP:RHHVF)

453.46 -11.55 (-2.48%)

Streaming Delayed Price Updated: 12:48 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Roche Holding Div RTS

< Previous 1 2 3 4 5 6 Next >

FDA Approves Expanded Use Of Roche's Influenza Treatment ↗

August 12, 2022

Via Benzinga

Amgen's Lumakras/Keytruda/Tecentriq Combo Data Flags Safety Concern ↗

August 08, 2022

Via Benzinga

Poseida Shares Rally As Roche Takes Next Big Step Into Allogeneic CAR-T Field ↗

August 03, 2022

Via Benzinga

Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product ↗

July 25, 2022

Via Benzinga

Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners ↗

July 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Roche's Long-Time CEO Passes Baton, Higher Diagnostics, Medicine Sales Lift 1H Sales & Profit ↗

July 21, 2022

Via Benzinga

Roche Launches Dual Antigen & Antibody Hepatitis C Diagnostic Test ↗

July 18, 2022

Via Benzinga

New Data Reinforce Favorable Safety, Efficacy Of Roche's Hemlibra For Hemophilia A ↗

July 11, 2022

Via Benzinga

Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial ↗

July 06, 2022

Via Benzinga

The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate ↗

July 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients ↗

June 16, 2022

Via Benzinga

Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients ↗

June 06, 2022

Via Benzinga

Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer ↗

May 23, 2022

Via Benzinga

Genentech's Tiragolumab/Tecentriq Fails On Progression Free Survival In PD-L1-High Metastatic Lung Cancer ↗

May 11, 2022

Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced results from its Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab in PD-L1-high locally advanced or metastatic non-small cell lung...

Via Benzinga

Roche Releases More Evrysdi Data For Very Young Infants With SMA ↗

April 29, 2022

Via Benzinga

Roche's CEO Warns Russia-Ukraine War Causing Problems For Multiple Sclerosis Trials ↗

April 25, 2022

The development of Roche Holdings AG's (OTC: RHHBY) multiple sclerosis candidate fenebrutinib is negatively impacted by Russia's ongoing invasion of Ukraine.

Via Benzinga

COVID-19 Tests Boost Roche's Q1 Sales, Reaffirms FY22 Outlook ↗

April 25, 2022

Via Benzinga

EMA' Advisory Committee Recommends Approval For Roche's Two Cancer Drugs ↗

April 22, 2022

Via Benzinga

FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis ↗

April 20, 2022

The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was...

Via Benzinga

Read Why Pliant Therapeutics Shares Are Soaring Today ↗

April 13, 2022

Pliant Therapeutics Inc (NASDAQ: PLRX) says that with just two FDA-approved Idiopathic Pulmonary Fibrosis drugs, it believes that is a high unmet need.

Via Benzinga

Genentech's Ocrevus Shows Benefit In Disability Progression & Cognitive Decline In Multiple Sclerosis ↗

April 04, 2022

Via Benzinga

FDA Grants Priority Review To Roche's Actemra For Hospitalized COVID-19 Adults ↗

April 04, 2022

Via Benzinga

Roche's Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial ↗

March 30, 2022

Roche Holding AG's (OTC: RHHBY) Phase 3 SKYSCRAPER-02 study in extensive-stage small-cell lung cancer (ES-SCLC)

Via Benzinga

Drug makers, Scientists Working For Long COVID Treatments: Reuters ↗

March 25, 2022

Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,

Via Benzinga

Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population ↗

March 16, 2022

Via Benzinga

Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy ↗

March 15, 2022

Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus...

Via Benzinga

Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial ↗

February 18, 2022

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab...

Via Benzinga

Roche Expects Slower FY22 Sales Growth On Lower Demand For COVID-19 Tests ↗

February 03, 2022

Roche Holdings AG's (OTC: RHHBY) FY21 sales increased 8% Y/Y (9% on a constant currency basis) to CH

Via Benzinga

Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues ↗

February 02, 2022

Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year,

Via Benzinga

Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab ↗

February 01, 2022

Biogen Inc (NASDAQ: BIIB) has

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Roche Holding Div RTS (OP:RHHVF)

Headline News about Roche Holding Div RTS

Starting at $3.75/week.

Subscribe Today